Used primarily in medical research and clinical studies, this compound is investigated for its potential to reverse multidrug resistance in cancer treatments. It acts as an inhibitor of P-glycoprotein, a protein that cancer cells often overexpress to pump out chemotherapeutic drugs, thereby reducing their effectiveness. By blocking this protein, it aims to enhance the intracellular concentration of anticancer drugs, improving therapeutic outcomes. Studies are ongoing to evaluate its efficacy and safety when combined with other chemotherapy agents, particularly in resistant cancers like ovarian, lung, and breast cancer. Additionally, it is explored in preclinical models to understand its pharmacokinetics and pharmacodynamics better.